12,123 Shares in Celgene Co. (NASDAQ:CELG) Purchased by Usca Ria LLC

Share on StockTwits

Usca Ria LLC purchased a new position in shares of Celgene Co. (NASDAQ:CELG) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 12,123 shares of the biopharmaceutical company’s stock, valued at approximately $1,121,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in CELG. Archford Capital Strategies LLC lifted its holdings in Celgene by 277.8% during the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 200 shares in the last quarter. Liberty Wealth Management LLC lifted its holdings in Celgene by 212.8% during the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 200 shares in the last quarter. Investors Research Corp bought a new stake in Celgene during the 1st quarter valued at about $28,000. Weaver Consulting Group bought a new stake in Celgene during the 1st quarter valued at about $29,000. Finally, Alera Investment Advisors LLC lifted its holdings in Celgene by 109.9% during the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 167 shares in the last quarter. Institutional investors own 74.19% of the company’s stock.

Shares of NASDAQ:CELG traded up $1.43 during trading hours on Friday, hitting $94.74. The company’s stock had a trading volume of 2,572,000 shares, compared to its average volume of 3,866,949. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $98.97. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32. The company has a market capitalization of $66.13 billion, a price-to-earnings ratio of 12.45, a P/E/G ratio of 0.44 and a beta of 1.46. The firm’s fifty day moving average price is $92.80 and its 200 day moving average price is $92.51.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.44 by $0.17. The business had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.16 EPS. On average, equities research analysts predict that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on CELG shares. Mizuho reiterated a “buy” rating and set a $103.00 price objective on shares of Celgene in a report on Wednesday, July 3rd. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 3rd. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a report on Tuesday, July 23rd. Cowen reiterated a “hold” rating and set a $102.00 price objective on shares of Celgene in a report on Tuesday, July 30th. Finally, ValuEngine lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $94.81.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: What is the Quick Ratio?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.